A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS ‐102 in irinotecan‐refractory metastatic colorectal cancer patients
International Journal of Cancer · 15.05.2024 · 154 (10) · 1794-1801
DOI: 10.1002/ijc.34845 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, online erschienen am 05.02.2024. Verfasst von Valerie Lee und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neutropenia. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Stand Up To Cancer, Astex Pharmaceuticals, AACR-VARI SU2C Epigenetics Dream Team.
Themen: Onkologische Pflege
Abstract (Originalsprache)
DNA methyltransferase inhibitors (DNMTi) have demonstrated benefit in reversing resistance to systemic therapies for several cancer types. In a phase II trial of guadecitabine and irinotecan compared to regorafenib or TAS‐102 in pts with advanced mCRC refractory to irinotecan. Patients with mCRC refractory to irinotecan were randomized 2:1 to guadecitabine and irinotecan (Arm A) vs standard of care regorafenib or TAS‐102 (Arm B) on a 28‐day cycle. Between January 15, 2016 and October 24, 2018, 104 pts were randomized at four international sites, with 96 pts undergoing treatment, 62 in Arm A and 34 in Arm B. Median overall survival was 7.15 months for Arm A and 7.66 months for Arm B (HR 0.93, 95% CI: 0.58–1.47, P = .75). The Kaplan–Meier rates of progression free survival at 4 months were 32% in Arm A and 26% in Arm B. Common ≥Grade 3 treatment related adverse events in Arm A were neutropenia (42%), anemia (18%), diarrhea (11%), compared to Arm B pts with neutropenia (12%), anemia (12%). Guadecitabine and irinotecan had similar OS compared to standard of care TAS‐102 or regorafenib, with evidence of target modulation. Clinical trial information: NCT01896856.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- School of Medicine, University of Southern California, Los Angeles, California, USA.
- Van Andel Institute, Grand Rapids, Michigan, USA.
ORCID-Profile: Valerie Lee, Henk Verheul
Förderung
- Stand Up To Cancer
- Astex Pharmaceuticals
- AACR-VARI SU2C Epigenetics Dream Team
Zitieren
APA
Lee, V., Parkinson, R., Zahurak, M., Cope, L., Cercek, A., Verheul, H., Gootjes, E., Lenz, H. J., Iqbal, S., Jones, P., Baylin, S., Rami, V., Ahuja, N., El Khoueiry, A., & Azad, N. S. (2024). A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS ‐102 in irinotecan‐refractory metastatic colorectal cancer patients. International Journal of Cancer, 154(10), 1794-1801. https://doi.org/10.1002/ijc.34845
Vancouver
Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, et al. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS ‐102 in irinotecan‐refractory metastatic colorectal cancer patients. International Journal of Cancer. 2024;154(10):1794-1801. doi:10.1002/ijc.34845
BibTeX
@article{Lee2024,
author = {Lee, Valerie and Parkinson, Rose and Zahurak, Marianna and Cope, Leslie and Cercek, Andrea and Verheul, Henk and Gootjes, Elske and Lenz, Heinz Josef and Iqbal, Syma and Jones, Peter and Baylin, Stephen and Rami, Vandna and Ahuja, Nita and El Khoueiry, Anthony and Azad, Nilofer S},
title = {A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS ‐102 in irinotecan‐refractory metastatic colorectal cancer patients},
journal = {International Journal of Cancer},
year = {2024},
volume = {154},
number = {10},
pages = {1794--1801},
doi = {10.1002/ijc.34845}
}
EUVIMED